An anonymous director reports

CIPHER PHARMACEUTICALS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Cipher Pharmaceuticals Inc. held its annual and special meeting of shareholders earlier today. All matters put forward before shareholders for consideration and approval, as set out in the company's management information circular dated May 2, 2025, were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the reappointment of RSM Canada LLP as auditor of the company, and the resolution approving the unallocated shares, rights and other entitlements under the company's share purchase plan. A total of approximately 13 million shares, representing approximately 50.9 per cent of the total shares outstanding, were represented in person or by proxy at the meeting. The detailed results of the vote for the election of directors of Cipher are set out in an attached table.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the United States and South America.